Oncopeptides AB (publ) announced that more information regarding the formal request from the U.S. Food and Drug Administration (FDA) to voluntarily withdraw Pepaxto's approval in the U.S has been made available by the FDA. The public docket contains, among other documents, a detailed appeal document outlining Oncopeptides' arguments for why Pepaxto should remain on the U.S. market as an important treatment option for multiple myeloma patients in later lines of treatment.